The use of AI in drug discovery has healthcare companies excited, as Milford Investment Analyst Dr Deborah Lambie discovered on her recent visit to the United States. She shared her findings on AM today, including the cost and time-saving benefits of using AI in developing new drugs. Deb also discusses the weight-loss drug race – with companies moving away from injection-based drugs to oral, and also looks into what it means for healthcare in New Zealand as Baby Boomers start to hit their 80s in 2026.